Cargando…

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies

BACKGROUND/AIMS: The efficacy and safety of mepolizumab in patients with severe eosinophilic asthma has been evaluated in a global clinical trial programme. This post hoc analysis assesses the efficacy and safety of mepolizumab in Korean patients. METHODS: Data from Korean patients in the Phase III,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Mi-Kyeong, Park, Hae-Sim, Park, Choon-Sik, Min, Soung-Jun, Albers, Frank C., Yancey, Steven W., Mayer, Bhabita, Kwon, Namhee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969054/ https://www.ncbi.nlm.nih.gov/pubmed/32450626 http://dx.doi.org/10.3904/kjim.2019.198

Ejemplares similares

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
por: Albers, Frank C., et al.
Publicado: (2019)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
por: Pavord, Ian D, et al.
Publicado: (2021)

Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
por: Wardlaw, Andrew, et al.
Publicado: (2020)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
por: Prazma, Charlene M, et al.
Publicado: (2021)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
por: Magnan, A., et al.
Publicado: (2016)

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
por: Albers, Frank C., et al.
Publicado: (2019)

From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases
por: Pavord, Ian D., et al.
Publicado: (2021)

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma
por: Gupta, Atul, et al.
Publicado: (2019)

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
por: Terrier, Benjamin, et al.
Publicado: (2023)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET
por: Liu, Mark C., et al.
Publicado: (2022)

Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome
por: Pane, Fabrizio, et al.
Publicado: (2022)

Mensa sonora ; Sonata representativa
por: Biber, Heinrich Ignaz Franz, 1644-1704
Publicado: (1988)

The hot corona of YY Mensae
por: Güdel, M, et al.
Publicado: (1996)

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
por: Liu, Mark C., et al.
Publicado: (2021)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis
por: Condreay, Lynn D., et al.
Publicado: (2020)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
por: Ghassemian, Arian, et al.
Publicado: (2021)

Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma
por: Albers, Frank C., et al.
Publicado: (2022)

Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma
por: Park, Hae-Sim, et al.
Publicado: (2019)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
por: Pavord, Ian D., et al.
Publicado: (2022)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Emotion Perception in Members of Norwegian Mensa
por: Egeland, Jens
Publicado: (2019)

Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome
por: Reiter, Andreas, et al.
Publicado: (2022)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Varricchi, Gilda, et al.
Publicado: (2016)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
por: Matsuno, Osamu, et al.
Publicado: (2019)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Emma, Rosalia, et al.
Publicado: (2018)

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice
por: Montero-Pérez, Olalla, et al.
Publicado: (2019)

Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma
por: Kobayashi, Konomi, et al.
Publicado: (2021)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
por: Pavord, Ian, et al.
Publicado: (2023)

Differential effects of short- and long-term treatment with mepolizumab on eosinophil kinetics in blood and sputum in eosinophilic asthma
por: Hassani, Marwan, et al.
Publicado: (2021)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Commentary: Emotion Perception in Members of Norwegian Mensa
por: Vaskinn, Anja
Publicado: (2019)

Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
por: Mukherjee, Manali, et al.
Publicado: (2017)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
por: Pelaia, Corrado, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_agj5h9rue3bna9futlsro9lob3